PRFX
Prf Technologies Ltd
NASDAQ · Pharmaceuticals
$2.96
-0.06 (-2.05%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.33M | 3.45M | 3.63M |
| Net Income | 722.6K | 805.0K | 796.5K |
| EPS | — | — | — |
| Profit Margin | 21.7% | 23.3% | 21.9% |
| Rev Growth | -7.5% | +9.4% | +15.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 4.88M | 5.12M | 5.00M |
| Total Equity | 8.55M | 7.87M | 7.95M |
| D/E Ratio | 0.57 | 0.65 | 0.63 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.33M | 1.25M | 1.35M |
| Free Cash Flow | 449.2K | 396.5K | 453.1K |